![Neil Miller](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Neil Miller
Gründer bei NRG Therapeutics Ltd.
Aktive Positionen von Neil Miller
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Direktor/Vorstandsmitglied | 01.01.2018 | - |
Vorstandsvorsitzender | 01.01.2018 | - | |
Gründer | 01.01.2018 | - |
Karriereverlauf von Neil Miller
Ehemalige bekannte Positionen von Neil Miller
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Auspherix Ltd.
![]() Auspherix Ltd. BiotechnologyHealth Technology Auspherix Ltd. operates as an early stage anti-infectives company which develops novel antibiotics to treat resistant bacterial diseases. The firm uses a library screening approach to identify drugs with novel mechanisms of action as antibiotics. The company was founded by Ian Charles and Dagmar Alber in 2013 and is headquartered in Stevenage, the United Kingdom. | Vorstandsvorsitzender | - | 30.04.2019 |
Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Neil Miller
The University of Liverpool | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 4 |
Operativ
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Auspherix Ltd.
![]() Auspherix Ltd. BiotechnologyHealth Technology Auspherix Ltd. operates as an early stage anti-infectives company which develops novel antibiotics to treat resistant bacterial diseases. The firm uses a library screening approach to identify drugs with novel mechanisms of action as antibiotics. The company was founded by Ian Charles and Dagmar Alber in 2013 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Commercial Services |
- Börse
- Insiders
- Neil Miller
- Erfahrung